Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.
So just what is Google up to? All we know for sure right now is that CEO Larry Page has expressed some rather vague but gigantic goals for the newly created company Calico, such as significantly adding on to the expected lifespan for humans while tackling health issues related to aging.
A three-gene biomarker could be used as a predictor of prostate cancer growth to help doctors identify which patients need earlier treatment.
Lung cancer causes more deaths than any other cancer worldwide, and late diagnosis often contributes to high mortality rates. But now, researchers think they may have a key to spotting the disease earlier: a protein that's present in high levels in lung cancers and can be detected in the blood.
A recent review of patients with breast cancer show that about 40% of women showed a change in at least one of these biomarkers between preliminary and principal treatment, an occurrence that might indicate a better chance of non-recurring survival.
A new analysis published in The New England Journal of Medicine found that RAS mutations--beyond the understood KRAS exon 2 mutations--can be used to predict a lack of response to Vectibix plus the oxaliplatin-based chemotherapy FOLFOX.
Investigators say that a biomarker in the blood--carbohydrate antigen 125, or CA125--offers a shot at a relatively low-cost approach to identifying ovarian cancer at an early stage, while the chances of survival are much higher.
A new Australian study showed that the glycoprotein MUC1 is overexpressed in peritoneal mesothelioma, a rare abdominal cancer caused by exposure to asbestos, and could serve as a prognostic tool in determining the severity of the deadly disease.
AstraZeneca is rolling the dice on a $500 million deal--including $225 million upfront--to buy the early-stage cancer immunology specialist Amplimmune for its U.S. biologics arm MedImmune. AstraZeneca is promising up to $275 million in development milestones.
Shares of Memphis-based GTx were eviscerated this morning after the biotech reported that a pair of Phase III studies of a muscle drug for cancer patients had failed.